home / stock / cyad / cyad quote
Last: | $0.47 |
---|---|
Change Percent: | -10.64% |
Open: | $0.52 |
Close: | $0.47 |
High: | $0.528 |
Low: | $0.47 |
Volume: | 49,047 |
Last Trade Date Time: | 05/18/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.47 | $0.52 | $0.47 | $0.528 | $0.47 | 49,047 | 05-18-2023 |
$0.5287 | $0.55 | $0.5287 | $0.5558 | $0.5287 | 9,402 | 05-17-2023 |
$0.5558 | $0.573 | $0.5558 | $0.59 | $0.535 | 28,366 | 05-16-2023 |
$0.635 | $0.56 | $0.635 | $0.635 | $0.52 | 14,814 | 05-15-2023 |
$0.59 | $0.589 | $0.59 | $0.65 | $0.55 | 7,545 | 05-12-2023 |
$0.615 | $0.58 | $0.615 | $0.65 | $0.5303 | 16,994 | 05-11-2023 |
$0.58 | $0.5937 | $0.58 | $0.5937 | $0.55 | 9,305 | 05-10-2023 |
$0.5701 | $0.5697 | $0.5701 | $0.5937 | $0.5201 | 23,032 | 05-09-2023 |
$0.5499 | $0.6101 | $0.5499 | $0.6393 | $0.5348 | 53,840 | 05-08-2023 |
$0.619 | $0.58 | $0.619 | $0.6997 | $0.58 | 44,582 | 05-05-2023 |
$0.679899 | $0.63 | $0.679899 | $0.68 | $0.6 | 25,183 | 05-04-2023 |
$0.62 | $0.58 | $0.62 | $0.69 | $0.58 | 4,578 | 05-03-2023 |
$0.6 | $0.6701 | $0.6 | $0.6701 | $0.6 | 3,199 | 05-02-2023 |
$0.6701 | $0.69 | $0.6701 | $0.7 | $0.612001 | 6,564 | 05-01-2023 |
$0.72 | $0.67 | $0.72 | $0.76 | $0.66 | 4,464 | 04-28-2023 |
$0.7201 | $0.675 | $0.7201 | $0.7201 | $0.67 | 9,493 | 04-27-2023 |
$0.6875 | $0.6617 | $0.6875 | $0.705 | $0.6601 | 5,201 | 04-26-2023 |
$0.7118 | $0.67 | $0.7118 | $0.7118 | $0.67 | 7,489 | 04-25-2023 |
$0.707 | $0.7633 | $0.707 | $0.7633 | $0.65 | 14,017 | 04-24-2023 |
$0.64 | $0.6 | $0.64 | $0.7 | $0.58 | 8,565 | 04-21-2023 |
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...